Tremfya’s ulcerative colitis approval on Wednesday comes as Johnson & Johnson’s blockbuster immunotherapy Stelara continues to face growing competition from biosimilars.

In an effort to build its commercial capacity, Moderna on Thursday announced it is lowering research and development spending, while pushing back its target for breaking even by two years to 2028.

Sanofi will join Big Pharma peers Novartis, BMS and Eli Lilly in radioligands, striking a $110 million licensing deal with RadioMedix and Orano Med to develop AlphaMedix for neuroendocrine tumors.

As it nears a crucial FDA action date for its transthyretin amyloid cardiomyopathy candidate, BridgeBio focuses on its late-stage pipeline.

When doses werer increased rapidly in a Phase I study, patients on Roche’s investigational oral GLP-1 receptor agonist experienced nausea, vomiting, constipation, diarrhea, as well as abdominal and ...

In this episode, Lori and guests discuss practical approaches regarding artificial intelligence and investor and industry confidence in its current state.

For the first eight months of 2024, California had the most job postings live on BioSpace—37.7% more than Massachusetts. Last year, Massachusetts ranked No.1 for the same time period.

An appreciation for practicality, independent thinking and patient care can help disrupt the bureaucracy of Big Pharma.

The late-stage clinical trial results showed that Eli Lilly’s once-weekly insulin efsitora matched daily injections for ...

A study published Tuesday in The New England Journal of Medicine showed that children between the ages of six and 12 who took ...

No patients have received Casgevy, CRISPR Therapeutics and Vertex Pharmeceuticals’ recently approved sickle cell gene therapy ...

BioMarin’s new business strategy leaves investors with questions; Lykos CEO steps down; Terns releases compelling data on ...